#1 PRESCRIBED MIGRAINE TREATMENT IN ITS CLASS SINCE 8/6/2021*

*Per IQVIA as oral brand in class (oral CGRP receptor antagonists): number one prescribed and number one in new prescriptions, since 8/6/21. Data current as of 11/22.

For the acute treatment of migraine and the preventive treatment of episodic migraine in adults

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

DID YOU KNOW 49% OF PATIENTS OFTEN DELAY OR AVOID TREATING THEIR MIGRAINES?[1,†]

Keep reading to help ensure your patients have enough medication for their migraine needs

†Based on a 2001-2002 survey conducted at a major national retail pharmacy in the US completed by 690 patients with a physician diagnosis of migraine.

Ellie W.
Actual Nurtec ODT patient.
Triggers: School-related stress, menstrual cycle.
Individual results may vary.

Patients were invited to share their treatment experience.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.

Please see additional Important Safety Information on the next page and click here for full Prescribing Information.

#1 PRESCRIBED MIGRAINE TREATMENT IN ITS CLASS SINCE 8/6/2021*

For the acute treatment of migraine and the preventive treatment of episodic migraine in adults

Help your patients treat and prevent their migraines with enough tablets to last throughout the month[2,‡]

- Nurtec ODT treats & prevents ALL IN ONE.[2]
- Nurtec ODT 75 mg is supplied in a carton containing an 8-pack; prescribe one or two 8-packs to meet your patients' individual needs each month.[2,‡]
- The safety of using more than 18 doses in a 30-day period has not been established.[2]

ADAPT TO YOUR PATIENTS' NEEDS, INCLUDING PREDICTABLE, UNAVOIDABLE, AND PLANNED TRIGGERS[2,3]

Evan has approximately 4 migraine attacks per month.

Evan B.
Actual Nurtec ODT patient since 2020.
Individual results may vary.

Jennifer has 10-12 headache days per month.

Jennifer F.
Actual Nurtec ODT patient since 2021.
Individual results may vary.

Greg's migraine attacks are triggered by stress. His migraines stem from traumatic brain injury and concussions sustained in combat.

Greg P.
Actual Nurtec ODT patient since 2021.
Individual results may vary.

Tia's migraine attacks are triggered by her menstrual cycle. She also has 3-5 migraine attacks at other times of the month.

Tia E.
Actual Nurtec ODT patient since 2020.
Individual results may vary.

CONSIDER PRESCRIBING UP TO TWO 8-PACKS PER MONTH TO ENSURE YOUR PATIENTS' INDIVIDUAL NEEDS ARE COVERED.

Patients were invited to share their treatment experience.

*Per IQVIA as oral brand in class (oral CGRP receptor antagonists): number one prescribed and number one in new prescriptions, since 8/6/21. Data current as of 11/22.

‡Quantity limits may apply per health plan.

SELECT IMPORTANT SAFETY INFORMATION (continued)

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp.

Please see additional Important Safety Information on the next page and click here for full Prescribing Information.

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

PROVEN EFFICACY IN ACUTE & PREVENTIVE TREATMENT TRIALS[2]

ACUTE TREATMENT

Delivered freedom from pain and most bothersome symptom (MBS)[2]

At 2 hours after a single dose of Nurtec ODT (co-primary endpoints):

- **21.2% of patients achieved migraine pain freedom** vs 10.9% on placebo (*P*<.001).[2]
- **35.1% achieved freedom from MBS** vs 26.8% on placebo (*P*=.001).[2]

PREVENTIVE TREATMENT

Reduced monthly migraine days (MMDs)[2]

During weeks 9 through 12 (primary endpoint):

- **Patients on treatment had a 4.3-day reduction from baseline in mean MMDs** vs a 3.5-day reduction in those taking placebo (*P*=.01).[2,§]

86% DID NOT TAKE RESCUE MEDICATION IN THE ACUTE TREATMENT TRIAL[2]

Within 24 hours post-dose (select secondary endpoint):

- **86% of patients in the Nurtec ODT group did not take a rescue medication** (including OTCs) vs 71% in the placebo group (*P*<.001).[2,¶]

NO ADVERSE EVENT GREATER THAN 3% IN CLINICAL TRIALS[2]

- In the pivotal trials, there were no serious treatment-related AEs reported by the Nurtec ODT groups.[4,5,‖]
- The most common AE with acute dosing was nausea (Nurtec ODT 2%; placebo 0.4%).[2]
- The most common AEs in the preventive study were nausea (rimegepant 2.7%; placebo 0.8%) and abdominal pain/dyspepsia (rimegepant 2.4%; placebo 0.8%).[2]

FOR PREVENTIVE TREATMENT, JUST ONE 75 MG DOSE OF NURTEC ODT IS NEEDED EVERY OTHER DAY[2]

Please see study designs on the next page.

AE=adverse event; CGRP=calcitonin gene-related peptide; OTC=over-the-counter medication

§Analyzed using a generalized linear mixed-effects model with treatment group, preventive migraine medication use at randomization, study month, and month-by-treatment group interaction as fixed effects and participant as random effect.[5]

¶Patients who took rescue medication were included in the analysis and classified as failures.[4]

‖A serious adverse event is any event that meets any of the following criteria at any dose: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a subject who received rimegepant, and others.[6]

SELECT IMPORTANT SAFETY INFORMATION & INDICATIONS (continued)

Use in Specific Populations: *Pregnancy:* It is not known if Nurtec ODT can harm an unborn baby. *Lactation*: The transfer of rimegepant into breastmilk is low (<1%). *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment:* Avoid use in patients with end-stage renal disease.

INDICATIONS

Nurtec ODT is indicated in adults for the:

- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

Please see additional Important Safety Information on the next page and click here for full Prescribing Information.

ROBUST SUPPORT YOU AND YOUR PATIENTS CAN COUNT ON

Eligible, commercially insured patients pay as little as $0 with the Nurtec ODT Copay Card.**

Additionally, Nurtec ODT is covered on all major formularies: UnitedHealthcare, Cigna, Aetna, Tricare, and Anthem.††

Over 96% of commercially insured patients have access to Nurtec ODT—that's over 286.3 million individuals, across all channels.††

Learn more about the only migraine medication that treats and prevents all in one[2,5]

Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. **The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. For any questions, please call 1-800-761-1568, visit nurtec.com/copay-terms or write to Pfizer Inc. at PO Box 29387, Mission, KS 66201. For full terms and conditions, please visit nurtec.com/savings#terms-and-conditions.

††Managed Markets Insights & Technology LLC since 1/10/23.

STUDY DESIGNS

For the acute treatment of migraine with or without aura in adults, Nurtec ODT was evaluated in a multi-center, double-blind, randomized, placebo-controlled study in which 1466 patients were randomized to Nurtec ODT (n=732) or placebo (n=734) and 1351 patients were evaluated for efficacy (n=669; n=682, respectively). The co-primary endpoints at 2 hours for Nurtec ODT vs placebo were pain freedom and freedom from most bothersome symptom; predefined as photophobia, phonophobia, or nausea.[2]

For the preventive treatment of episodic migraine in adults, rimegepant 75 mg was evaluated in a multi-center, double-blind, randomized, placebo-controlled study in which 747 patients were randomized to rimegepant 75 mg (n=373) or placebo (n=374) and 695 patients were evaluated for efficacy (n=348; n=347, respectively). The primary endpoint was change from baseline in the mean number of monthly migraine days during weeks 9 through 12.[2]

INDICATIONS

Nurtec ODT is indicated in adults for the:

- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp.

Use in Specific Populations: *Pregnancy:* It is not known if Nurtec ODT can harm an unborn baby. *Lactation:* The transfer of rimegepant into breastmilk is low (<1%). *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment:* Avoid use in patients with end-stage renal disease.

Please click here for full Prescribing Information.

References: 1. Foley A, Cady R, Martin V, et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. *Headache.* 2005;45(5):538-545. doi:10.1111/j.1526-4610.2005.05107.x **2.** Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. **3.** Health Union, LLC. *Migraine in America 2020*. Health Union, LLC; 2020. **4.** Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. *Lancet*. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X **5.** Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. *Lancet*. 2020;397(10268): 51-60. doi:10.1016/S0140-6736(20)32544-7 **6.** Study BHV3000-303 Clinical Protocol. Clinical Trials.Gov. https://clinicaltrials.gov/ProvidedDocs/57/NCT03461757/Prot_000.pdf. Published July 23, 2018. Accessed January 13, 2023.

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg